Dermira Inc (NASDAQ:DERM) CEO Thomas G. Wiggans acquired 23,419 shares of Dermira stock in a transaction on Monday, August 19th. The shares were purchased at an average cost of $8.54 per share, with a total value of $199,998.26. Following the completion of the acquisition, the chief executive officer now owns 39,666 shares of the company’s stock, valued at approximately $338,747.64. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.
Dermira stock opened at $9.23 on Thursday. Dermira Inc has a one year low of $6.00 and a one year high of $15.48. The business has a fifty day moving average price of $8.49 and a 200-day moving average price of $9.67. The company has a debt-to-equity ratio of 4.95, a current ratio of 8.42 and a quick ratio of 8.08. The firm has a market capitalization of $465.65 million, a P/E ratio of -1.76 and a beta of 1.33.
Dermira (NASDAQ:DERM) last posted its quarterly earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.57. Dermira had a negative return on equity of 478.29% and a negative net margin of 306.91%. The firm had revenue of $66.65 million during the quarter, compared to analyst estimates of $34.16 million. Sell-side analysts expect that Dermira Inc will post -4.51 earnings per share for the current fiscal year.
Several institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. boosted its holdings in shares of Dermira by 10.2% in the second quarter. Vanguard Group Inc. now owns 2,333,482 shares of the biopharmaceutical company’s stock worth $22,308,000 after acquiring an additional 216,449 shares during the period. Oracle Investment Management Inc. boosted its holdings in shares of Dermira by 28.7% in the second quarter. Oracle Investment Management Inc. now owns 1,760,072 shares of the biopharmaceutical company’s stock worth $16,826,000 after acquiring an additional 392,636 shares during the period. Dimensional Fund Advisors LP boosted its holdings in shares of Dermira by 2.5% in the fourth quarter. Dimensional Fund Advisors LP now owns 943,421 shares of the biopharmaceutical company’s stock worth $6,783,000 after acquiring an additional 22,816 shares during the period. JPMorgan Chase & Co. boosted its holdings in shares of Dermira by 76.4% in the second quarter. JPMorgan Chase & Co. now owns 782,223 shares of the biopharmaceutical company’s stock worth $7,025,000 after acquiring an additional 338,828 shares during the period. Finally, Jacobs Levy Equity Management Inc. boosted its holdings in shares of Dermira by 68.5% in the first quarter. Jacobs Levy Equity Management Inc. now owns 763,590 shares of the biopharmaceutical company’s stock worth $10,347,000 after acquiring an additional 310,551 shares during the period. 93.51% of the stock is owned by hedge funds and other institutional investors.
Several brokerages have weighed in on DERM. Mizuho raised Dermira from a “neutral” rating to a “buy” rating and reduced their price objective for the company from $17.00 to $14.00 in a report on Thursday, June 6th. BidaskClub lowered Dermira from a “hold” rating to a “sell” rating in a report on Saturday, August 17th. Cantor Fitzgerald reissued a “buy” rating and set a $25.00 price objective on shares of Dermira in a report on Friday, May 3rd. HC Wainwright reissued a “buy” rating on shares of Dermira in a report on Wednesday, May 8th. Finally, Zacks Investment Research lowered Dermira from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 13th. Two analysts have rated the stock with a sell rating, two have assigned a hold rating and eight have issued a buy rating to the company’s stock. Dermira presently has an average rating of “Buy” and a consensus target price of $17.72.
Dermira Company Profile
Dermira, Inc, a biopharmaceutical company, develops and commercializes therapies for patients with dermatologic diseases in the United States. The company offers QBREXZA, a topical once-daily anticholinergic cloth for the treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older.
Featured Article: Discount Rate
Receive News & Ratings for Dermira Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dermira and related companies with MarketBeat.com's FREE daily email newsletter.